Hyloris Pharmaceuticals SA (FRA:52U)

Market Cap	140.00M -17.5%
Revenue (ttm)	7.94M -9.5%
Net Income	-6.33M
EPS	-0.23
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	4.850
Previous Close	4.880
Day's Range	4.850 - 4.850
52-Week Range	4.480 - 8.140
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 30, 2026

About Hyloris Pharmaceuticals

Hyloris Pharmaceuticals SA engages in the research, development, and manufacture of pharmaceutical products to address medical needs. The company offers Maxigesic IV, a combination of paracetamol and ibuprofen used for post-operative pain, the opioid crisis, and acute pain; Podofilox Gel, an antimycotic drug for the treatment of external genital and perianal warts caused by various types of the human papilloma virus; and Sotalol IV to treat atrial fibrillation. It also develops Aspirin IV and HY-074 IV to reduce the risk of morbidity and mortal...

• Industry: Pharmaceutical Preparations
• Founded: 2012
• Employees: 55
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 52U

Financial Performance

In 2025, Hyloris Pharmaceuticals's revenue was 8.83 million, a decrease of -9.50% compared to the previous year's 9.76 million. Losses were -6.33 million, -0.13% less than in 2024.